Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer. Antonia, S., Kim, S., Spira, A. I., Ahn, M., Ou, S., Stjepanovic, N., Fasolo, A., Jagert, D., Ottt, P., Wainberg, Z. A., Wakelee, H. A., Goldman, J., Kurland, J., Rebelatto, M. C., Yao, W., Gupta, A., Blake-Haskins, J. A., Segal, N. AMER SOC CLINICAL ONCOLOGY. 2016
View details for DOI 10.1200/JCO.2016.34.15_suppl.9029
View details for Web of Science ID 000404711506177